Immix Biopharma Investor Presentation Deck slide image

Immix Biopharma Investor Presentation Deck

3 Optimal Tumor Binding While Ensuring High Expression COBRA Binder COBRA Binder Leads with Heavy Chain Proven Linker of Heavy and Light Chain Employed .. IHSL VH (GGGGS)5 VL LSH VL (GGGGS) 5 VH Biomarker Research ㅏ - Source:: Moreno-Cortes E,. et al Front Oncol. 2023; Mazinani M, et al. Biomark Res. 2022. 3.6 1.6 Day 10 CAR-T Expansion (10^7) HSL LSH 80 76 Specific Cytotoxicity (%): JeKo1 (ROR1+) co-culture HSL LSH doi: 10.3389/fonc.2023.1200914 "Glycine (Gly) and serine (Ser) residues provide the flexibility necessary for antigen-binding sites to change conformation and maintain good stability in aqueous solutions... prevent[ing] formation of secondary structures and reduc[ing] likelihood of the linker interfering with the folding and function of the scFv" September 19, 2022 doi: 10.1186/s40364-022-00417-w ● ●●● IMMIX S BIOPHARMA NXC-201 COBRA Binder: Heavy Chain - Proven Linker - Light Chain Configuration, enabling: Rapid, Sustained CAR- T Expansion ✓ Improved Cytotoxicity in the presence of antigen 12
View entire presentation